We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEX Beats Q1 Earnings Estimates on HST Momentum, Raises View
Read MoreHide Full Article
Key Takeaways
IDEX Q1 EPS rose 14.3% and beat estimates, sales grew 8.9% on strong HST demand.
IEX saw robust growth in AI-linked data centers, semiconductors and defense markets.
Record orders and raised 2026 guidance reflect improving demand and confidence.
IDEX Corporation (IEX - Free Report) delivered first-quarter 2026 adjusted earnings of $2.00 per share, topping the Zacks Consensus Estimate of $1.78 by 12.4%. The metric rose 14.3% year over year. Net sales of $886.9 million beat the consensus mark of $835 million by 6.2% and increased 8.9% from the year-ago quarter.
Results were driven by solid traction in the Health & Science Technologies segment, where higher volumes in AI-linked data center power and semiconductor end markets, along with strength in space and defense, supported growth. IDEX also posted record orders, signaling improving demand early in 2026.
Organic sales increased 5% year over year. While acquisitions/divestitures had a positive impact on sales of 1%, foreign currency translation had a positive impact of 3% on sales.
IDEX Corporation Price, Consensus and EPS Surprise
Net sales from the Fluid & Metering Technologies segment totaled $301.5 million, up 4% year over year. Our estimate for segmental net sales was $297.3 million. Organic sales increased 2% year over year. Foreign currency translation had a positive impact of 2% on sales.
Net sales from the Health & Science Technologies segment totaled $398.4 million, up 17% year over year. Organic sales increased 11% year over year. Acquisitions/divestitures and foreign currency translation had a positive impact of 3% each on sales.
Net sales from the Fire & Safety/Diversified Products segment totaled $188.3 million, which increased 2% year over year. Our estimate for segmental net sales was $182 million. Organic sales decreased 1% on a year-over-year basis, while foreign currency translation had a favorable impact of 3% on sales.
IEX’s Orders Signal Broad-Based Demand
Orders increased 13% year over year to $988.3 million, with organic orders up 10%. Management pointed to momentum and backlog building in businesses tied to several end markets, particularly AI-driven areas, pharma and space and defense.
IDEX’s Margin Profile
IDEX’s cost of sales increased 9.7% year over year to $488.8 million. The adjusted gross margin was 44.9%, down 40 basis points year over year, reflecting unfavorable mix and higher costs, partially offset by productivity improvements and volume leverage. Selling, general and administrative expenses increased to $218.3 million from $209.4 million in the prior-year period.
Adjusted EBITDA rose 10.8% to $230.4 million and the adjusted EBITDA margin improved 50 basis points to 26%. Operating income increased 21.4% to $172.4 million, aided by stronger operating performance and a lower restructuring and asset impairment burden compared to the prior year period. The operating margin was 19.4%, up 200 bps year over year. Interest expenses (net) were relatively stable year over year at $16 million.
IEX’s Cash Uses Highlight Shareholder Returns
Cash flows from operating activities were $103.7 million compared with $105.7 million a year ago, as increased earnings were offset by customer payment timing. Free cash flow declined 5.9% to $86 million, reflecting both working-capital timing and higher capital expenditures of $17.7 million.
The company continued to return capital, repurchasing $76.3 million of stock and paying $52.8 million in dividends during the quarter. On the balance sheet, cash and cash equivalents were $586.2 million exiting the first quarter, while long-term borrowings (net) stood at $1.87 billion.
IDEX’s Raised 2026 Outlook Reflects Confidence
Management raised full-year 2026 guidance, projecting organic sales growth of 3-4% compared with prior expectations of 1-2%. The company also lifted its full-year adjusted earnings outlook to $8.35-$8.55 per share from $8.15-$8.35 previously.
For the second quarter of 2026, IDEX expects organic sales to increase 3-4% from the year-ago period and expects adjusted earnings in the range of $2.07-$2.12.
Zacks Rank and Stocks to Consider
The company currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks are discussed below:
DXP Enterprises’ earnings surpassed the consensus estimate by 52.8% in the last reported quarter. In the past 60 days, the Zacks Consensus Estimate for DXPE’s 2026 earnings has increased by 17.2%.
Nordson Corporation (NDSN - Free Report) currently carries a Zacks Rank #2 (Buy). Nordson’s earnings topped the consensus estimate in each of the trailing four quarters. The average earnings surprise was 2.5%. In the past 60 days, the Zacks Consensus Estimate for Nordson’s fiscal 2026 earnings has increased 0.5%.
RBC Bearings (RBC - Free Report) presently carries a Zacks Rank of 2. RBC Bearings’ earnings surpassed the consensus estimate in each of the trailing four quarters. The average earnings surprise was 5.3%. In the past 60 days, the Zacks Consensus Estimate for RBC Bearings’ fiscal 2026 earnings has inched down 0.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
IDEX Beats Q1 Earnings Estimates on HST Momentum, Raises View
Key Takeaways
IDEX Corporation (IEX - Free Report) delivered first-quarter 2026 adjusted earnings of $2.00 per share, topping the Zacks Consensus Estimate of $1.78 by 12.4%. The metric rose 14.3% year over year. Net sales of $886.9 million beat the consensus mark of $835 million by 6.2% and increased 8.9% from the year-ago quarter.
Results were driven by solid traction in the Health & Science Technologies segment, where higher volumes in AI-linked data center power and semiconductor end markets, along with strength in space and defense, supported growth. IDEX also posted record orders, signaling improving demand early in 2026.
Organic sales increased 5% year over year. While acquisitions/divestitures had a positive impact on sales of 1%, foreign currency translation had a positive impact of 3% on sales.
IDEX Corporation Price, Consensus and EPS Surprise
IDEX Corporation price-consensus-eps-surprise-chart | IDEX Corporation Quote
Segmental Details
Net sales from the Fluid & Metering Technologies segment totaled $301.5 million, up 4% year over year. Our estimate for segmental net sales was $297.3 million. Organic sales increased 2% year over year. Foreign currency translation had a positive impact of 2% on sales.
Net sales from the Health & Science Technologies segment totaled $398.4 million, up 17% year over year. Organic sales increased 11% year over year. Acquisitions/divestitures and foreign currency translation had a positive impact of 3% each on sales.
Net sales from the Fire & Safety/Diversified Products segment totaled $188.3 million, which increased 2% year over year. Our estimate for segmental net sales was $182 million. Organic sales decreased 1% on a year-over-year basis, while foreign currency translation had a favorable impact of 3% on sales.
IEX’s Orders Signal Broad-Based Demand
Orders increased 13% year over year to $988.3 million, with organic orders up 10%. Management pointed to momentum and backlog building in businesses tied to several end markets, particularly AI-driven areas, pharma and space and defense.
IDEX’s Margin Profile
IDEX’s cost of sales increased 9.7% year over year to $488.8 million. The adjusted gross margin was 44.9%, down 40 basis points year over year, reflecting unfavorable mix and higher costs, partially offset by productivity improvements and volume leverage. Selling, general and administrative expenses increased to $218.3 million from $209.4 million in the prior-year period.
Adjusted EBITDA rose 10.8% to $230.4 million and the adjusted EBITDA margin improved 50 basis points to 26%. Operating income increased 21.4% to $172.4 million, aided by stronger operating performance and a lower restructuring and asset impairment burden compared to the prior year period. The operating margin was 19.4%, up 200 bps year over year. Interest expenses (net) were relatively stable year over year at $16 million.
IEX’s Cash Uses Highlight Shareholder Returns
Cash flows from operating activities were $103.7 million compared with $105.7 million a year ago, as increased earnings were offset by customer payment timing. Free cash flow declined 5.9% to $86 million, reflecting both working-capital timing and higher capital expenditures of $17.7 million.
The company continued to return capital, repurchasing $76.3 million of stock and paying $52.8 million in dividends during the quarter. On the balance sheet, cash and cash equivalents were $586.2 million exiting the first quarter, while long-term borrowings (net) stood at $1.87 billion.
IDEX’s Raised 2026 Outlook Reflects Confidence
Management raised full-year 2026 guidance, projecting organic sales growth of 3-4% compared with prior expectations of 1-2%. The company also lifted its full-year adjusted earnings outlook to $8.35-$8.55 per share from $8.15-$8.35 previously.
For the second quarter of 2026, IDEX expects organic sales to increase 3-4% from the year-ago period and expects adjusted earnings in the range of $2.07-$2.12.
Zacks Rank and Stocks to Consider
The company currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks are discussed below:
DXP Enterprises (DXPE - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
DXP Enterprises’ earnings surpassed the consensus estimate by 52.8% in the last reported quarter. In the past 60 days, the Zacks Consensus Estimate for DXPE’s 2026 earnings has increased by 17.2%.
Nordson Corporation (NDSN - Free Report) currently carries a Zacks Rank #2 (Buy). Nordson’s earnings topped the consensus estimate in each of the trailing four quarters. The average earnings surprise was 2.5%. In the past 60 days, the Zacks Consensus Estimate for Nordson’s fiscal 2026 earnings has increased 0.5%.
RBC Bearings (RBC - Free Report) presently carries a Zacks Rank of 2. RBC Bearings’ earnings surpassed the consensus estimate in each of the trailing four quarters. The average earnings surprise was 5.3%. In the past 60 days, the Zacks Consensus Estimate for RBC Bearings’ fiscal 2026 earnings has inched down 0.3%.